Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: Assessment using transient elastometry and the role of HCV genotype 3

Clinical Infectious Diseases

Volumn 42, Issue 7, 2006, Pages 1032-1039

  Barreiro, Pablo ^a   Martín Carbonero, Luz ^a   Núñez, Marina ^a   Rivas, Pablo ^a   Morente, Adolfo ^a   Simarro, Nuria ^a   Labarga, Pablo ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 ANTIGEN; INTERFERON; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; COMORBIDITY; CONFIDENCE INTERVAL; DIAGNOSTIC VALUE; DISEASE COURSE; ELASTOMETRY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; POPULATION DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TRANSIENT ELASTOMETRY;

ADULT; AGE FACTORS; ALANINE TRANSAMINASE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RNA, VIRAL;

EID: 33645083707     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/501021     Document Type: Article

References (44)

1. Ryder S. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53:451-5.
2. Poynard T, Mathurin P, Lai C, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257-65.
3. Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17:1467-71.
4. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32:492-7.
5. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and HCV coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-8.
6. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 depletion in patients coinfected with hepatitis C virus and HIV. J Infect Dis 2001; 183:134-7.
7. Martín-Carbonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-33.
8. Benhamou Y, De Martino V, Bochet M, Poynard T. Factors affecting liver fibrosis in HIV and hepatitis C virus coinfected patients: impact of protease inhibitor therapy. Hepatology 2001; 34:283-7.
9. Tural C, Fuster D, Tor J, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus co-infected patients. J Viral Hepat 2003; 10:118-25.
10. Macías J, Castellano V, Merchante N, et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 2004; 18:767-74.
11. Nuñez M, Soriano V. Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients. J Hepatol 2005; 42:290-2.
12. Yoo T, Donfield S, Lail A, Lynn H, Daar E. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005; 191:4-10.
13. Tedeschi R, Pivetta E, Zanussi S, et al. Quantification of hepatitis C virus in liver specimens and sera from patients with HIV coinfection by using Versant HCV RNA 3.0 (branched DNA-based) assay. J Clin Microbiol 2003; 41:3046-50.
14. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53:406-12.
15. Bravo A, Sheth S, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500.
16. Afdhal N. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37:972-4.
17. Regev A, Berho M, Jeffers L, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-8.
18. Sandrin L, Fourquet B, Hasquenoph J, et al. Transient elastography: a new non-invasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-13.
19. Ziol M, Handra-Luca A, Kettaneh A, et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41:48-54.
20. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, fibrotest, APR1 and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:43-50.
21. Bedossa P, Poynard T. An algorithm for grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-93.
22. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection: updated recommendations from the HIV-HCV International Panel. AIDS 2004; 18:1-12.
23. Bissell D. Sex and hepatic fibrosis. Hepatology 1999; 29:988-9.
24. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52:574-9.
25. Cholet F, Nousbaum I, Richecoeur M, et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 2004; 28:272-8.
26. Adinolfi L, Gambardella M, Andreana A, Tripodi M, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-64.
27. De Mendoza C, Soriano V. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antivir Ther 2005; 10(Suppl 2):109-15.
28. Fleming C, Craven D, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and HIV coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36:97-100.
29. Rauch A, Egger M, Reichen I, Furrer H. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-α plus ribavirin. The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2005; 38:238-40.
30. Day C, James O. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114:842-5.
31. Lonardo A, Adinolfi L, Loria P, Carulli N, Ruggiero G, Day C. Steatosis and hepatitis C virus: mechanism and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126:586-97.
32. Nuñez M, Soriano V. Hepatitis C virus (HCV) genotypes and disease progression in HIV/HCV-coinfected patients. J Infect Dis 2005; 191:1-3.
33. Núñez M, Rios P, Martín-Carbonero L, Pérez-Olmeda M, González-Lahoz I, Soriano V. Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 30:65-8.
34. Torti C, Lapadula G, Puoti M, et al. The influence of genotype 3 hepatitis C virus co-infection on liver enzyme elevation in HIV-positive patients after commencement of a new HAART regimen: results from the EPOKA-MASTER cohort. J Acquir Immune Defic Syndr 2006; 41:180-5.
35. Sharma P, Balan V, Hernandez J, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci 2004; 49:25-9.
36. Hui J, Sud A, Farrell G, et al. Chronic hepatitis C virus infection and insulin resistance: how do they interact, and what is the effect on hepatic fibrosis? Gastroenterology 2003; 125:1695-704.
37. Aranzabal L, Casado J, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-93.
38. Sulkowski M, Mehta S, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-92.
39. Monto A, Dove L, Bostrom A, Kakar S, Tien P, Wright T. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42:310-6.
40. Martín-Carbonero L, Soriano V. Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. AIDS 2005; 19:621-3.
41. Berger A, Prondzinski M, Doerr H, Rabenau H, Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 1996; 48:339-43.
42. Garcia F, Roldán C, Hernández-Quero J, et al. Relationship between viral genotype and viral load in patients with chronic hepatitis C. Eur J Clin Microbiol Infect Dis 1996; 15:884-7.
43. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825-32.
44. Alberti A, Noventa F, Benvegnu L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137:961-4.